Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 56.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 490,165 shares of the medical research company’s stock after selling 643,147 shares during the period. Handelsbanken Fonder AB owned approximately 0.08% of Edwards Lifesciences worth $36,287,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Wellington Management Group LLP raised its stake in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Jennison Associates LLC purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth $555,939,000. Assenagon Asset Management S.A. boosted its holdings in Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after acquiring an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in shares of Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after purchasing an additional 2,606,950 shares in the last quarter. Finally, Seilern Investment Management Ltd acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $109,490,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on EW. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Piper Sandler boosted their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 12th. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, Citigroup increased their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $79.95.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Up 0.0 %

Shares of NYSE EW opened at $74.71 on Friday. The firm has a fifty day moving average of $72.86 and a 200-day moving average of $69.86. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $44.06 billion, a PE ratio of 10.72, a P/E/G ratio of 4.89 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.